Previous 10 | Next 10 |
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Listen on the go! A daily podcast of Wall Street Breakfast will be available on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks closed lower on Friday to wrap up a second straight week of losses while bonds rallied, as investors sought safety from the tensions between Russia and Ukraine a...
As liquidity is drained and capital becomes more discerning, the ability to correctly evaluate “select” businesses is paramount. As opportunity sets improve, the importance of knowing our sweet spots increases, notes money manager Matthew Castel, in the Logos LP Blog. For furt...
Street firms are having different reactions to Charles River Laboratories' (CRL -1.9%) Q4 2021 results, in which it beat on the top and bottom lines. Citi's Patrick Donnelly upgraded the stock to buy from neutral and maintained his target price of $400 (~31% upside based on Wednesday's close)...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Charles River Laboratories International, Inc. (CRL) Q4 2021 Results Earnings Conference Call February 16, 2022, 08:30 AM ET Company Participants Todd Spencer - Corporate Vice President, Investor Relations James Foster - Chairman, President and Chief Executive Officer David Smith - Corporate ...
Charles River Laboratories International (CRL -2.6%) stock declined following its Q4 results, which beat analysts' estimates, and a reaffirmed 2022 guidance. Q4 total revenue increased ~14.4% Y/Y to $905.05M. The company said acquisitions contributed 5.9% to consolidated Q4 revenue growth. Th...
Shares of Charles River Laboratories (CRL -4.4%) are struggling today even though the company posted Q4 2021 results that beat on the top and bottom lines. The company also reaffirmed its 2022 guidance, including non-GAAP EPS estimate $11.50–$11.75. However, at least one Street analyst...
The following slide deck was published by Charles River Laboratories International, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Charles River Laboratories International, Inc. 2021 Q4 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Charles River Laboratories International Inc. Company Name:
CRL Stock Symbol:
NYSE Market:
Charles River Laboratories International Inc. Website:
Clinical trials for AAV9 gene therapy bolstered with plasmid and viral vector CDMO expertise Charles River Laboratories International, Inc. (NYSE: CRL) announced today a collaboration with the FOXG1 Research Foundation (FRF) highlighting the patient advocacy group’s model t...
Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics Under the agreement, Charles River will make an equity investment in Aut...
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2024 financial results on Wednesday, August 7 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 7 th , at 9:00 a.m. ET. Investors wi...